Business Context and Reporting Period
This Form 8-K Current Report was filed by Nemus Bioscience, Inc. (not Skye Bioscience, Inc.) on August 20, 2015. The filing discloses the closing of a private placement financing and the entry into related material definitive agreements, including Lock-Up Agreements with officers and directors and a Registration Rights Agreement with investors.
Key Financial Metrics and Transaction Details
- Financing Amount: The Company raised an aggregate of $5,000,000.
- Securities Issued:
- 5,000 shares of Series B Preferred Stock (stated value $1,000 per share).
- Warrants to purchase 6,250,000 shares of common stock.
- Warrant Terms: Exercise price of $1.15 per share; term of five years.
- Conversion Terms: Preferred Stock is convertible into common stock at a price of $0.80 per share.
- Placement Agent Fees: Midtown Partners & Co., LLC received a cash fee of $213,000 plus warrants to purchase 187,500 shares of common stock at $1.15 per share.
- Liquidity and Debt: The filing does not provide specific data on total cash balances, existing debt, or operating margins. The transaction represents a capital raise intended to improve liquidity.
Material Changes and Agreements
- Lock-Up Agreements: Officers and directors agreed to refrain from selling common stock for 90 days after the earlier of (i) the effectiveness of a registration statement for resale or (ii) eligibility for sale under Rule 144.
- Registration Rights: The Company agreed to file a registration statement within 30 days to register 130% of the shares underlying the Preferred Stock and all shares underlying the Warrants.
- Penalty Provision: If the registration statement is not effective within specified timeframes, the Company must pay investors 2.0% of the aggregate purchase price per month until effectiveness or Rule 144 eligibility is achieved.
- Force Conversion: The Company may force conversion of Preferred Stock if the VWAP exceeds 200% of the conversion price ($0.80) for 20 trading days with daily volume exceeding 200,000 shares.
Outlook, Risks, and Unusual Items
- Regulatory Compliance: The securities were issued under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D to accredited investors without general solicitation.
- Dilution Risk: Warrant holders are restricted from exercising if it would result in them holding more than 4.99% of the outstanding common stock.
- Cashless Exercise: Warrants may be exercised on a cashless basis, meaning the Company would receive no proceeds from such exercises.
- Management Commentary: The filing references a press release (Exhibit 99.1) for further details but does not contain specific forward-looking guidance or operational outlook within the text of the 8-K itself.
Investor Verification Checklist
- Verify the exact number of outstanding common shares to calculate the dilution impact of the 6,250,000 warrants and the 6,250,000 shares underlying the Preferred Stock (5,000 shares x $1,000 / $0.80 conversion price).
- Confirm the Company's current cash position post-closing to assess runway for operations.
- Review the full text of the Registration Rights Agreement to understand the specific timelines triggering the 2.0% monthly penalty payments.
- Check the status of the registration statement filing required within 30 days of August 20, 2015.
- Examine the press release (Exhibit 99.1) for any additional strategic use of proceeds not detailed in the 8-K.